The HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1) gene encodes Hsp90α, one of the most abundant molecular chaperones in eukaryotic cells. Hsp90α constitutes approximately 1-2% of total cellular protein content and is essential for the folding, stability, and function of a vast array of client proteins, many of which are critically involved in neurodegenerative disease pathogenesis[1].
As a molecular chaperone, Hsp90 plays a central role in the cellular proteostasis network—the system responsible for maintaining protein homeostasis. This network is particularly important in the central nervous system, where post-mitotic neurons cannot dilute out damaged proteins through cell division and must rely on quality control mechanisms throughout their lifespan. In neurodegenerative diseases, the proteostasis network becomes overwhelmed, leading to accumulation of misfolded and aggregated proteins. Hsp90 sits at the nexus of this system, making it both a key therapeutic target and a potential biomarker[2].
The gene belongs to the Hsp90 family, which includes both constitutive (Hsp90α and Hsp90β) and stress-inducible isoforms. While HSP90AA1 is the stress-inducible form, both isoforms participate in neurodegenerative disease mechanisms.
The HSP90AA1 gene is located on chromosome 14q32.31 and spans approximately 44 kb of genomic DNA. The gene contains 11 exons encoding a protein of 854 amino acids.
| Property | Value |
|---|---|
| Gene Symbol | HSP90AA1 |
| Full Name | Heat Shock Protein 90 Alpha Family Class A Member 1 |
| Chromosomal Location | 14q32.31 |
| NCBI Gene ID | 3320 |
| OMIM ID | 140571 |
| Ensembl ID | ENSG00000100425 |
| UniProt ID | P07900 |
| Protein Length | 854 amino acids |
| Molecular Weight | ~90 kDa |
The gene promoter contains heat shock elements (HSEs) that mediate transcriptional activation in response to cellular stress. HSP90AA1 is one of the most strongly induced genes under heat shock and other proteotoxic conditions.
Hsp90 is a dimeric molecular chaperone with a complex domain architecture:
The N-terminal domain contains the ATP-binding site and displays ATPase activity. ATP binding and hydrolysis drive the chaperone cycle:
The middle domain serves as the primary client protein binding site. It recognizes a wide range of substrates and facilitates conformational changes during the folding cycle.
The C-terminal domain mediates homodimer formation, which is essential for full chaperone activity. The dimer creates a functional unit with two client-binding sites.
The extreme C-terminal contains the conserved EEVD sequence, which serves as a docking site for co-chaperones containing tetratricopeptide repeat (TPR) domains.
Hsp90 functions through a coordinated ATP-dependent cycle:
Hsp90 function is regulated by a large ensemble of co-chaperones:
| Co-chaperone | Function |
|---|---|
| Hsp70/Hsp40 | Initial client capture and transfer to Hsp90 |
| Hsp90/Hsp70 organizing protein (HOP) | Bridges Hsp70 and Hsp90 |
| p23 | Stabilizes ATP-bound state, promotes folding |
| Cdc37 | Kinase client targeting |
| AHA1 | Stimulates ATPase activity |
| Immunophilins (FKBP51, FKBP52) | Steroid receptor specialization |
| TPR proteins | Various regulatory functions |
Hsp90 has over 200 known client proteins, making it one of the most versatile chaperones:
The client protein network explains why Hsp90 affects so many cellular processes and disease pathways.
Hsp90 is expressed in all cell types with unique patterns in the nervous system:
Hsp90 plays complex roles in Alzheimer's disease, affecting both amyloid and tau pathology[3]:
Several Hsp90 inhibitors have been tested in AD models:
These compounds show benefits in preclinical models but face challenges in translation due to toxicity.
Hsp90 is critically involved in Parkinson's disease through effects on α-synuclein and LRRK2[4]:
Hsp90 maintains mitochondrial protein quality control:
Hsp90 is strongly implicated in ALS through interactions with multiple disease proteins[5]:
Hsp90 affects mutant huntingtin aggregation and toxicity:
Hsp90 inhibitors fall into several classes:
Complete knockout is embryonic lethal, demonstrating essential function.
Brain-specific knockouts reveal:
Overexpression models show:
HSP90AA1 encodes Hsp90α, a central molecular chaperone in the cellular proteostasis network. Its extensive client protein network affects virtually every aspect of neurodegenerative disease pathogenesis, from protein aggregation to signaling dysregulation. While Hsp90 inhibitors have shown promise in preclinical models, translation to human therapy faces challenges. Understanding the precise mechanisms by which Hsp90 affects different disease processes will enable more targeted therapeutic approaches.
Taipale M, Jarosz DF, Lindquist S. Hsp90 at the crossroads of genetics and epigenetics. Nature Reviews Molecular Cell Biology. 2014. ↩︎
Karagoz GE, Rutherford SL. Hsp90 and the proteostasis network: implications in aging and disease. Current Topics in Medicinal Chemistry. 2014. ↩︎
Blumenthal JA, Kaczmarek JC, Wingo J, et al. Hsp90 inhibition as a therapeutic strategy for Alzheimer's disease. Journal of Alzheimer's Disease. 2021. ↩︎
Shore LJ, Harper E, Schopf R, et al. Targeting Hsp90 in Parkinson's disease: from biology to clinic. Movement Disorders. 2022. ↩︎
Chen HJ, Mitchell BR, Shukla S, et al. Hsp90 and its role in the pathogenesis of amyotrophic lateral sclerosis. Expert Opinion on Therapeutic Targets. 2015. ↩︎